Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.3
(6.56%)
HKD 1.3
(6.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 16.69 Million HKD | -67.44% |
| 2022 | 51.28 Million HKD | -97.42% |
| 2021 | 1.98 Billion HKD | 2430.34% |
| 2020 | 78.53 Million HKD | 23.98% |
| 2019 | 63.34 Million HKD | -84.86% |
| 2018 | 418.26 Million HKD | 79.86% |
| 2017 | 232.55 Million HKD | -7.72% |
| 2016 | 252 Million HKD | 10.02% |
| 2015 | 229.05 Million HKD | 18.78% |
| 2014 | 192.83 Million HKD | 28.15% |
| 2013 | 150.46 Million HKD | 32.21% |
| 2012 | 113.8 Million HKD | 35.64% |
| 2011 | 83.9 Million HKD | 44.6% |
| 2010 | 58.02 Million HKD | 25.14% |
| 2009 | 46.36 Million HKD | 65.25% |
| 2008 | 28.06 Million HKD | 146.79% |
| 2007 | 11.37 Million HKD | 427.76% |
| 2006 | -3.46 Million HKD | -2367.32% |
| 2005 | 153 Thousand HKD | 104.68% |
| 2004 | -3.26 Million HKD | 39.06% |
| 2003 | -5.36 Million HKD | -54.69% |
| 2002 | -3.46 Million HKD | -163.25% |
| 2001 | -1.31 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | 290.5 Thousand HKD | 0.0% |
| 2023 Q2 | 8.05 Million HKD | 0.0% |
| 2023 Q1 | 8.05 Million HKD | 162.65% |
| 2023 FY | 16.69 Million HKD | -67.44% |
| 2023 Q3 | 290.5 Thousand HKD | -96.4% |
| 2022 Q4 | -12.86 Million HKD | -137.58% |
| 2022 Q1 | 20.3 Million HKD | 110.97% |
| 2022 Q2 | 6.41 Million HKD | -68.4% |
| 2022 Q3 | 34.22 Million HKD | 433.33% |
| 2022 FY | 51.28 Million HKD | -97.42% |
| 2021 Q2 | 2.11 Billion HKD | 5050.44% |
| 2021 Q4 | -185.1 Million HKD | -1437.15% |
| 2021 FY | 1.98 Billion HKD | 2430.34% |
| 2021 Q3 | 13.84 Million HKD | -99.35% |
| 2021 Q1 | 41.04 Million HKD | 461.53% |
| 2020 FY | 78.53 Million HKD | 23.98% |
| 2020 Q1 | 39.89 Million HKD | -11.75% |
| 2020 Q2 | 57.08 Million HKD | 43.09% |
| 2020 Q3 | 25.02 Million HKD | -56.16% |
| 2020 Q4 | 7.31 Million HKD | -70.79% |
| 2019 FY | 63.34 Million HKD | -84.86% |
| 2019 Q3 | 42.05 Million HKD | 585.57% |
| 2019 Q4 | 45.2 Million HKD | 7.51% |
| 2019 Q1 | 46.95 Million HKD | -78.73% |
| 2019 Q2 | -8.66 Million HKD | -118.44% |
| 2018 Q4 | 220.79 Million HKD | 207.95% |
| 2018 Q2 | 55.59 Million HKD | -20.78% |
| 2018 Q1 | 70.17 Million HKD | 53.68% |
| 2018 FY | 418.26 Million HKD | 79.86% |
| 2018 Q3 | 71.69 Million HKD | 28.97% |
| 2017 Q2 | 78.69 Million HKD | 69.66% |
| 2017 Q1 | 46.38 Million HKD | -19.72% |
| 2017 FY | 232.55 Million HKD | -7.72% |
| 2017 Q3 | 61.82 Million HKD | -21.43% |
| 2017 Q4 | 45.66 Million HKD | -26.14% |
| 2016 Q4 | 57.77 Million HKD | -20.65% |
| 2016 Q3 | 72.81 Million HKD | 6.59% |
| 2016 Q1 | 53.1 Million HKD | -17.59% |
| 2016 Q2 | 68.31 Million HKD | 28.63% |
| 2016 FY | 252 Million HKD | 10.02% |
| 2015 FY | 229.05 Million HKD | 18.78% |
| 2015 Q3 | 61.58 Million HKD | -1.59% |
| 2015 Q2 | 62.58 Million HKD | 54.72% |
| 2015 Q1 | 40.44 Million HKD | -28.15% |
| 2015 Q4 | 64.44 Million HKD | 4.64% |
| 2014 Q2 | 44.97 Million HKD | 6.82% |
| 2014 Q3 | 49.46 Million HKD | 9.99% |
| 2014 Q4 | 56.29 Million HKD | 13.8% |
| 2014 FY | 192.83 Million HKD | 28.15% |
| 2014 Q1 | 42.1 Million HKD | 8.32% |
| 2013 Q2 | 41.44 Million HKD | 28.27% |
| 2013 Q3 | 37.84 Million HKD | -8.68% |
| 2013 Q4 | 38.86 Million HKD | 2.69% |
| 2013 FY | 150.46 Million HKD | 32.21% |
| 2013 Q1 | 32.31 Million HKD | 14.75% |
| 2012 FY | 113.8 Million HKD | 35.64% |
| 2012 Q3 | 31.17 Million HKD | 4.4% |
| 2012 Q1 | 24.6 Million HKD | -8.59% |
| 2012 Q2 | 29.86 Million HKD | 21.35% |
| 2012 Q4 | 28.15 Million HKD | -9.69% |
| 2011 Q1 | 16.89 Million HKD | 0.0% |
| 2011 Q4 | 26.92 Million HKD | 13.94% |
| 2011 FY | 83.9 Million HKD | 44.6% |
| 2011 Q2 | 16.46 Million HKD | -2.56% |
| 2011 Q3 | 23.62 Million HKD | 43.53% |
| 2010 FY | 58.02 Million HKD | 25.14% |
| 2010 Q2 | 15.57 Million HKD | 0.0% |
| 2009 Q2 | 12.28 Million HKD | 0.0% |
| 2009 FY | 46.36 Million HKD | 65.25% |
| 2008 FY | 28.06 Million HKD | 146.79% |
| 2007 FY | 11.37 Million HKD | 427.76% |
| 2006 FY | -3.46 Million HKD | -2367.32% |
| 2005 FY | 153 Thousand HKD | 104.68% |
| 2004 FY | -3.26 Million HKD | 39.06% |
| 2003 FY | -5.36 Million HKD | -54.69% |
| 2002 FY | -3.46 Million HKD | -163.25% |
| 2001 FY | -1.31 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 84.103% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 99.112% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 110.247% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 208.739% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 131.682% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 93.934% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 157.893% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 115.741% |
| SSY Group Limited | 1.31 Billion HKD | 98.734% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 87.201% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 93.745% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 99.567% |